file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 17722, GCS 106366, CR 136943 Collection span: 1963 - 2012 | |
Word(i) List (4568) Word count: 24159, All words count: 34321 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
1001 | HEARTS | 3 | 10 | 114 |
1002 | IMPAIRED | 2 | 2 | 114 |
1003 | INVESTIGATION | 6 | 10 | 114 |
1004 | PERFUSION | 6 | 13 | 114 |
1005 | SUBSET | 3 | 21 | 114 |
1006 | CHIMPANZEES | 2 | 29 | 113 |
1007 | CONTINUED | 3 | 29 | 113 |
1008 | CYCLOSPORINE-RELATED | 1 | 66 | 113 |
1009 | DRUG-MONITORING | 3 | 16 | 113 |
1010 | HEMOPOIETIC | 3 | 24 | 113 |
1011 | IMMUNOPATHOLOGIC | 1 | 1 | 113 |
1012 | LYMPHATIC | 5 | 33 | 113 |
1013 | NIFEDIPINE | 2 | 7 | 113 |
1014 | RESULTING | 2 | 8 | 113 |
1015 | TYPE | 13 | 13 | 113 |
1016 | HOMOTRANSPLANTATIONS | 1 | 32 | 112 |
1017 | PURIFICATION | 3 | 33 | 112 |
1018 | T-LYMPHOCYTES | 4 | 10 | 112 |
1019 | ANTI-LYMPHOCYTIC | 5 | 19 | 111 |
1020 | DORSAL | 2 | 10 | 111 |
1021 | DYSPLASIA | 1 | 1 | 111 |
1022 | FIBROMUSCULAR | 1 | 1 | 111 |
1023 | INVESTIGATIVE | 2 | 8 | 111 |
1024 | QUANTITATION | 4 | 28 | 111 |
1025 | 2ND | 2 | 5 | 110 |
1026 | ALLOGRAFTED | 2 | 9 | 110 |
1027 | CELL-MEDIATED | 3 | 13 | 110 |
1028 | PLASMA-LEVELS | 2 | 39 | 110 |
1029 | ANTI-SCHISTOSOMAL | 1 | 6 | 109 |
1030 | CYTOTOXICITY | 3 | 6 | 109 |
# | Word | Recs | TLCS | TGCS |
1031 | DEFICIENCY | 2 | 9 | 109 |
1032 | DOSE-DEPENDENT | 3 | 8 | 109 |
1033 | HEPATOCYTE | 5 | 7 | 109 |
1034 | LIPID-METABOLISM | 2 | 14 | 109 |
1035 | MODIFIED | 8 | 20 | 109 |
1036 | MOLECULES | 5 | 8 | 109 |
1037 | PATTERN | 4 | 16 | 109 |
1038 | RELATIONSHIP | 8 | 32 | 109 |
1039 | CLINICOPATHOLOGICAL | 3 | 41 | 108 |
1040 | IMMUNOMODULATORY | 7 | 7 | 108 |
1041 | MONOCLONAL-ANTIBODY | 5 | 10 | 108 |
1042 | WHITE | 6 | 5 | 108 |
1043 | APOPTOTIC | 5 | 15 | 107 |
1044 | CORD | 2 | 10 | 107 |
1045 | GRANULOMATOUS | 2 | 0 | 107 |
1046 | SPINAL | 2 | 10 | 107 |
1047 | TIME | 6 | 25 | 107 |
1048 | ADHESION | 4 | 5 | 106 |
1049 | ADJUNCTIVE | 2 | 25 | 106 |
1050 | BRAVE | 1 | 1 | 106 |
1051 | LILLY | 1 | 1 | 106 |
1052 | LYMPHOKINE-ACTIVATED | 2 | 16 | 106 |
1053 | MORTALITY | 3 | 0 | 106 |
1054 | COLITIS | 2 | 0 | 105 |
1055 | INTERLEUKIN-2 | 6 | 29 | 105 |
1056 | PREDICTIVE | 4 | 6 | 105 |
1057 | PSORIASIS | 1 | 10 | 105 |
1058 | RELEVANCE | 3 | 54 | 105 |
1059 | REPOPULATION | 3 | 12 | 105 |
1060 | CROSSROADS | 1 | 1 | 104 |
# | Word | Recs | TLCS | TGCS |
1061 | FUNTION | 1 | 16 | 104 |
1062 | INTRAHEPATIC | 1 | 4 | 104 |
1063 | ISOMERASES | 1 | 1 | 104 |
1064 | LIMB | 14 | 35 | 104 |
1065 | MARKER | 6 | 6 | 104 |
1066 | PERIPHERAL-NERVE | 1 | 21 | 104 |
1067 | SITE | 1 | 4 | 104 |
1068 | 51CR-LABELLED | 1 | 6 | 103 |
1069 | FK506-BASED | 1 | 16 | 103 |
1070 | HEPATOCYTES | 10 | 21 | 103 |
1071 | IMMUNE-SYSTEM | 1 | 1 | 103 |
1072 | LYMPHOLD | 1 | 18 | 103 |
1073 | RHESUS-MONKEY | 1 | 1 | 103 |
1074 | AUTOLOGOUS | 5 | 15 | 102 |
1075 | MATURATION | 3 | 2 | 102 |
1076 | P450-3A | 1 | 19 | 102 |
1077 | PROINFLAMMATORY | 2 | 12 | 102 |
1078 | SALVAGE | 3 | 21 | 102 |
1079 | TOLERANCE-ASSOCIATED | 1 | 41 | 102 |
1080 | UTILITY | 2 | 5 | 102 |
1081 | ALLOSTIMULATORY | 3 | 29 | 101 |
1082 | DUCTOPENIA | 1 | 13 | 101 |
1083 | FISTULA | 3 | 9 | 101 |
1084 | INSITU | 3 | 9 | 101 |
1085 | LIVER-FAILURE | 1 | 13 | 101 |
1086 | NEPHROTOXIC | 3 | 11 | 101 |
1087 | AMPLIFICATION | 8 | 45 | 100 |
1088 | DETERMINANTS | 5 | 3 | 100 |
1089 | PCR | 11 | 49 | 100 |
1090 | PROCESSES | 2 | 18 | 100 |
# | Word | Recs | TLCS | TGCS |
1091 | PROSPECTIVE-STUDY | 2 | 4 | 100 |
1092 | FC-EPSILON-RI | 1 | 12 | 99 |
1093 | MEDIATORS | 1 | 12 | 99 |
1094 | MONONUCLEAR | 7 | 11 | 99 |
1095 | NEUROPROTECTIVE | 6 | 5 | 99 |
1096 | NONINHERITED | 1 | 6 | 99 |
1097 | PARAMETERS | 4 | 3 | 99 |
1098 | RESULT | 2 | 18 | 99 |
1099 | COMBINING | 5 | 35 | 98 |
1100 | CONJUNCTION | 2 | 7 | 98 |
1101 | INHIBITS | 9 | 9 | 98 |
1102 | CICLOSPORIN | 5 | 9 | 97 |
1103 | EXCRETION | 4 | 10 | 97 |
1104 | FK-506-TREATED | 4 | 16 | 97 |
1105 | HIGHLY | 3 | 0 | 97 |
1106 | INTRAVENOUS | 8 | 7 | 97 |
1107 | AXONS | 1 | 10 | 96 |
1108 | DEVELOP | 1 | 10 | 96 |
1109 | DIVERSION | 1 | 7 | 96 |
1110 | DONOR-RECIPIENT | 5 | 32 | 96 |
1111 | ILEAL | 1 | 7 | 96 |
1112 | MODELS | 6 | 6 | 96 |
1113 | NEUROTOXICITY | 3 | 6 | 96 |
1114 | POSSIBILITY | 1 | 20 | 96 |
1115 | PROFILES | 5 | 14 | 96 |
1116 | PROFILING | 1 | 10 | 96 |
1117 | SENSITIZATION | 3 | 15 | 96 |
1118 | WELL-TOLERATED | 1 | 20 | 96 |
1119 | ALTERNATE-DAY | 3 | 7 | 95 |
1120 | ANTISERA | 5 | 18 | 95 |
# | Word | Recs | TLCS | TGCS |
1121 | DEVELOPMENTS | 5 | 1 | 95 |
1122 | IDENTICAL | 4 | 18 | 95 |
1123 | MOLECULAR | 11 | 9 | 95 |
1124 | RADIATION | 4 | 13 | 95 |
1125 | ADMINISTERED | 4 | 7 | 94 |
1126 | APPEARANCES | 1 | 5 | 94 |
1127 | CD34 | 3 | 10 | 94 |
1128 | CIRCULATION | 2 | 1 | 94 |
1129 | GENERATION | 8 | 4 | 94 |
1130 | HYPERCHOLESTEROLEMIA | 1 | 1 | 94 |
1131 | INHIBITORS | 8 | 3 | 94 |
1132 | LIGHT-MICROSCOPIC | 1 | 5 | 94 |
1133 | MOTHER | 4 | 7 | 94 |
1134 | PREVENTING | 1 | 0 | 94 |
1135 | PROTOCOLS | 7 | 22 | 94 |
1136 | URINE | 2 | 20 | 94 |
1137 | ALLOCATION | 3 | 11 | 93 |
1138 | ALTERNATE | 1 | 11 | 93 |
1139 | MODERN | 4 | 8 | 93 |
1140 | REJECTING | 2 | 11 | 93 |
1141 | STEROID-FREE | 5 | 9 | 93 |
1142 | IMMUNIZATION | 5 | 9 | 92 |
1143 | MULTILINEAGE | 5 | 63 | 92 |
1144 | NODES | 2 | 0 | 92 |
1145 | PRIMARY-TREATMENT | 1 | 49 | 92 |
1146 | SMALL-BOWEL | 11 | 18 | 92 |
1147 | STIMULATION | 3 | 10 | 92 |
1148 | XENOGRAFTS | 10 | 13 | 92 |
1149 | COMPLEX | 8 | 9 | 91 |
1150 | CONSCIOUS | 1 | 8 | 91 |
# | Word | Recs | TLCS | TGCS |
1151 | CROSSMATCH-POSITIVE | 1 | 16 | 91 |
1152 | INSIGHTS | 1 | 14 | 91 |
1153 | MECHANISTIC | 1 | 14 | 91 |
1154 | MICROEMULSION | 3 | 3 | 91 |
1155 | REVERSIBLE | 2 | 13 | 91 |
1156 | UNUSUAL | 3 | 2 | 91 |
1157 | 5-YEAR | 1 | 3 | 90 |
1158 | ANTI-DONOR | 2 | 27 | 90 |
1159 | CHOLANGITIS | 2 | 4 | 90 |
1160 | CLUSTER | 1 | 3 | 90 |
1161 | GRAFT-VS-HOST | 7 | 17 | 90 |
1162 | RABBITS | 4 | 5 | 90 |
1163 | RHESUS | 5 | 8 | 90 |
1164 | SELECTED | 3 | 23 | 90 |
1165 | CALCINEURIN-A | 1 | 0 | 89 |
1166 | CASE-REPORT | 5 | 10 | 89 |
1167 | CONSERVED | 1 | 0 | 89 |
1168 | DEPENDS | 1 | 30 | 89 |
1169 | IMMUNOPHILIN-IMMUNOSUPPRESSANT | 1 | 0 | 89 |
1170 | IMMUNOTHERAPEUTIC | 2 | 4 | 89 |
1171 | PLASMA-RENIN | 2 | 3 | 89 |
1172 | PREVENTS | 9 | 6 | 89 |
1173 | QUANTITY | 1 | 30 | 89 |
1174 | REGIONS | 1 | 0 | 89 |
1175 | ALLOANTIGEN | 4 | 19 | 88 |
1176 | FK506-TREATED | 2 | 11 | 88 |
1177 | FUNCTIONAL-CHANGES | 2 | 11 | 88 |
1178 | INFLAMMATORY | 5 | 1 | 88 |
1179 | ISCHEMIA-REPERFUSION | 5 | 9 | 88 |
1180 | MATRIX | 3 | 3 | 88 |
# | Word | Recs | TLCS | TGCS |
1181 | RHEUMATOID | 2 | 0 | 88 |
1182 | TRACT | 2 | 4 | 88 |
1183 | CONTINUOUS | 2 | 19 | 87 |
1184 | RENAL-HOMOTRANSPLANT | 1 | 5 | 87 |
1185 | ROLES | 2 | 42 | 87 |
1186 | STABILITY | 1 | 59 | 87 |
1187 | 1-YEAR | 1 | 4 | 86 |
1188 | ANTIGEN-G | 1 | 2 | 86 |
1189 | CHILDHOOD | 3 | 2 | 86 |
1190 | CLAMPING | 1 | 34 | 86 |
1191 | END-STAGE | 3 | 3 | 86 |
1192 | EPIDERMAL | 2 | 1 | 86 |
1193 | GLUCOSE-METABOLISM | 4 | 21 | 86 |
1194 | HEPATIC-DYSFUNCTION | 1 | 34 | 86 |
1195 | HLA-G | 1 | 2 | 86 |
1196 | INTEGRITY | 2 | 12 | 86 |
1197 | MAB | 2 | 19 | 86 |
1198 | MMF | 1 | 4 | 86 |
1199 | NEUROPATHOLOGICAL | 1 | 0 | 86 |
1200 | OCCURRING | 1 | 12 | 86 |